Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer

Thomas S Frank¹, Xiaotian Sun², Yuqing Zhang³, Jingxuan Yang⁴, William E Fisher⁵, Marie-Claude Gingras⁶, Min Li⁷

Affiliations

¹ The Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA.
² The Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA; Department of Medicine, Department of Surgery, The University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1262A, Oklahoma City, OK 73104, USA; Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
³ Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
⁴ The Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA; Department of Medicine, Department of Surgery, The University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1262A, Oklahoma City, OK 73104, USA.
⁵ Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
⁶ Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA; Human Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza, N1519, Houston, TX 77030, USA. Electronic address: mgingras@bcm.edu.
⁷ The Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA; Department of Medicine, Department of Surgery, The University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1262A, Oklahoma City, OK 73104, USA. Electronic address: min-li@ouhsc.edu.

PMID: 25890222
PMCID: PMC4451193
DOI: 10.1016/j.canlet.2015.04.009

Review

Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer

Thomas S Frank et al. Cancer Lett. 2015.

. 2015 Jul 10;363(1):1-6.

doi: 10.1016/j.canlet.2015.04.009. Epub 2015 Apr 15.

Authors

Thomas S Frank¹, Xiaotian Sun², Yuqing Zhang³, Jingxuan Yang⁴, William E Fisher⁵, Marie-Claude Gingras⁶, Min Li⁷

Affiliations

¹ The Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA.
² The Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA; Department of Medicine, Department of Surgery, The University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1262A, Oklahoma City, OK 73104, USA; Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
³ Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
⁴ The Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA; Department of Medicine, Department of Surgery, The University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1262A, Oklahoma City, OK 73104, USA.
⁵ Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
⁶ Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA; Human Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza, N1519, Houston, TX 77030, USA. Electronic address: mgingras@bcm.edu.
⁷ The Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA; Department of Medicine, Department of Surgery, The University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1262A, Oklahoma City, OK 73104, USA. Electronic address: min-li@ouhsc.edu.

PMID: 25890222
PMCID: PMC4451193
DOI: 10.1016/j.canlet.2015.04.009

Abstract

Pancreatic cancer has the worst five-year survival rate of all malignancies due to its aggressive progression and resistance to therapy. Current therapies are limited to gemcitabine-based chemotherapeutics, surgery, and radiation. The current trend toward "personalized genomic medicine" has the potential to improve the treatment options for pancreatic cancer. Gene identification and genetic alterations like single nucleotide polymorphisms and mutations will allow physicians to predict the efficacy and toxicity of drugs, which could help diagnose pancreatic cancer, guide neoadjuvant or adjuvant treatment, and evaluate patients' prognosis. This article reviews the multifaceted roles of genomics and pharmacogenomics in pancreatic cancer.

Keywords: Gene therapy; Genomic profiling; Mutations; Pancreatic cancer; Pharmacogenomics; SLC39A4 (ZIP4).

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: none.

References

1. Gamba G. Initial sequence and analysis of the human genome. Rev Invest Clin. 2001;53:294–297. - PubMed
1. Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod N, Huang J, Kirkness EF, Denisov G, Lin Y, MacDonald JR, Pang AW, Shago M, Stockwell TB, Tsiamouri A, Bafna V, Bansal V, Kravitz SA, Busam DA, Beeson KY, McIntosh TC, Remington KA, Abril JF, Gill J, Borman J, Rogers YH, Frazier ME, Scherer SW, Strausberg RL, Venter JC. The diploid genome sequence of an individual human. PLoS biology. 2007;5:e254. - PMC - PubMed
1. Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, McGuire A, He W, Chen YJ, Makhijani V, Roth GT, Gomes X, Tartaro K, Niazi F, Turcotte CL, Irzyk GP, Lupski JR, Chinault C, Song XZ, Liu Y, Yuan Y, Nazareth L, Qin X, Muzny DM, Margulies M, Weinstock GM, Gibbs RA, Rothberg JM. The complete genome of an individual by massively parallel DNA sequencing. Nature. 2008;452:872–876. - PubMed
1. Mackay J, Szecsei CM. Genetic counselling for hereditary predisposition to ovarian and breast cancer. Ann Oncol. 2010;21(Suppl 7):vii334–338. - PubMed
1. Chua EW, Kennedy MA. Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics. Front Pharmacol. 2012;3:152. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer

Affiliations

Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical